Stavroula E. Giannouli

Athens, ESYE31, Greece

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications

Validation of the new IMS/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients.

Validation of the new IMS/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients.

Journal: HemaSphere
Published: March 09, 2026

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.

Journal: American journal of hematology
Published: January 30, 2026

Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies.

Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies.

Journal: British journal of haematology
Published: November 25, 2025

Primary Breast Lymphoma: A Rare Presentation of Diffuse Large B-Cell Lymphoma, Germinal Center B-Cell Subtype (DLBCL-GCB).

Primary Breast Lymphoma: A Rare Presentation of Diffuse Large B-Cell Lymphoma, Germinal Center B-Cell Subtype (DLBCL-GCB).

Journal: Cureus
Published: June 12, 2025

Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single Institution.

Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single Institution.

Journal: American journal of hematology
Published: May 05, 2025

Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström's Macroglobulinemia.

Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström's Macroglobulinemia.

Journal: Clinical lymphoma, myeloma & leukemia
Published: March 26, 2025

Growth differentiation factor-15 as a non-invasive biomarker of liver fibrosis in sickle cell disease.

Growth differentiation factor-15 as a non-invasive biomarker of liver fibrosis in sickle cell disease.

Journal: International journal of hematology
Published: March 19, 2025

Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies.

Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: February 05, 2025

Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring.

Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring.

Journal: Blood advances
Published: February 03, 2025

Lymphadenopathy is an independent prognostic factor for patients with Waldenström macroglobulinaemia.

Lymphadenopathy is an independent prognostic factor for patients with Waldenström macroglobulinaemia.

Journal: British journal of haematology
Published: January 31, 2025

Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis.

Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis.

Journal: Clinical lymphoma, myeloma & leukemia
Published: January 25, 2025

Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis.

Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis.

Journal: American journal of hematology
Published: January 08, 2025
Showing 1-12 of 43

Last Updated: 09/26/2026